Project Grant HT94252510114
Award Date
5/1/25
Completion Date
4/30/27
Dollars Obligated
$282K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19111, USA
Similar Awards
This $188,000 Project Grant was awarded on April 1, 2024 by the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), to The Institute For Cancer Research. The grant funds a research project titled "P2X7 RECEPTOR AS A NOVEL THERAPEUTIC TARGET IN PROSTATE CANCER" that will be conducted from April 1, 2024 through March 31, 2026. The Institute For Cancer Research, a non-profit subsidiary of Temple University, will carry out biomedical...
The U.S. Defense Health Agency awarded a $1,880,000 Project Grant to The Institute for Cancer Research, a non-profit subsidiary of Temple University, under the Military Medical Research and Development program (CFDA 12.420). The funding will support a 3-year research project to study the SRPK1-AKT signaling axis in endometrial cancer. As a prime grantee, The Institute for Cancer Research will conduct preclinical testing and analysis to develop new approaches for cancer prevention and...
The U.S. Department of Defense's Defense Health Agency awarded a $752,000 Project Grant to The Institute For Cancer Research, a subsidiary of Temple University, to investigate therapeutic response disparities in locally advanced rectal cancer. This grant, funded under the Military Medical Research and Development program (CFDA 12.420), supports basic, applied, and advanced biomedical research to transform health care for service members and the public through innovative and impactful...
The U.S. Defense Health Agency awarded a $700,788 Project Grant to The Institute For Cancer Research, a non-profit subsidiary of Temple University, under the Military Medical Research and Development program (CFDA 12.420). The funding supports a 3-year research project to study the targeting of the nuclear necroptosis pathway in the pancreatic cancer microenvironment. As a prime grantee, The Institute For Cancer Research will conduct preclinical testing, biomarker analysis, and other...
The federal Project Grant award of $846,000.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is supporting research by The Institute For Cancer Research, a non-profit organization and subsidiary of Temple University, to investigate PALB2 mutant breast cancer. The award, which runs from August 1, 2024 to July 31, 2027, will enable the Institute to conduct innovative scientific studies ranging from basic laboratory research to advanced...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,128,000 Project Grant to The Institute For Cancer Research to conduct research on "Restoring PALB2 Function as a Mechanism of PARP1 Resistance in BRCA1-Mutant EOC". The award, with a performance period from July 1, 2024 to June 30, 2028, supports innovative scientific research aimed at improving health outcomes for military service members, veterans, and the broader...
The federal Project Grant award in the amount of $499,999.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), funds research by the Institute of Cancer Research: Royal Cancer Hospital (The) to study the interplay of molecular and spatial architectures with clinical states in prostate cancer. The research project aims to make discoveries that defeat cancer through innovative biomedical research. As a subawardee, the Institute of...
The Institute For Cancer Research, a non-profit research organization and subsidiary of Temple University, was awarded a $534,445 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research to investigate NETRIN G1 ligand as a new immunomodulatory target and early biomarker in pancreatic cancer, with a project period from August 1, 2023 to July 31, 2026.
The Institute For Cancer Research has extensive...
The U.S. Defense Health Agency awarded a $1,513,169 Project Grant to Health Research, Inc. to support the "LEVERAGING POLYAMINE METABOLISM TO TARGET EPIGENOMIC ADAPTABILITY AND LINEAGE PLASTICITY IN PROSTATE CANCER" research project under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, beginning on April 1, 2024, aims to develop innovative approaches for treating prostate cancer by targeting tumor metabolism and epigenetic mechanisms. As a...
The Institute For Cancer Research has been awarded a $940,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct a mouse model study of epigenetic events in melanomagenesis. This 3-year grant, with a period of performance from July 1, 2024 to June 30, 2027, will enable the non-profit research organization to investigate the underlying epigenetic mechanisms driving the development of melanoma. As a prime grantee,...